



# TECHNOLOGY EVALUATION CONSORTIUM™

Quantitative Medicine Meeting with Pfizer and Amgen  
Friday, September 6, 2013  
Webinar

## **Cambridge Healthtech Associates**

Dawn Van Dam (General Manager)  
Amid Zand (Project Manager)  
Ernie Bush (Scientific Director)

### **Quantitative Medicine**

John King  
Geoff Hoare  
Joshua Kangas  
David Demosthenes  
John King  
Scott Bodine  
Geoff Hoare  
Joshua Kangas  
David Demosthenes  
*Jim Parrino (not on call)*  
*Bob Murphy (not on call)*  
*Jamie Grooms (not on call)*  
*Scott Bodine (not on call)*

### **Amgen**

Yudong He  
Padma Narayanan  
*Chuck Qualls (not on call)*  
*Helen McBride (not on call)*

### **Pfizer**

Yvonne Will  
Falgun Shah

## Agenda

- I) Opening Remarks and Introductions: Ernie (CHA) and John (Quantitative Medicine)
  - II) Interactive Discussion: Quantitative Medicine, Pfizer, and Amgen
  - III) Closing and Action Items
- 

### I) Opening Remarks and Introductions

Brief introductions and descriptions of responsibilities were discussed.

**Dawn Van Dam:** General Manager; CHA

**Amid:** Project Manager; CHA

**Ernie Bush:** Scientific Director; CHA

**Falgun Shah:** Compound Safety Prediction Department; background is in toxicoinformatics; Pfizer

**Yvonne Will:** Compound Safety Prediction Department; background in predictive *In vitro* assays; Pfizer

**Yudong He:** Computational biologist supporting the discovery program at Amgen

**Padma Narayanan:** Discovery Toxicology; background in amino and mitochondrial toxicity; point person for Engagement and Evaluation group; Amgen

**Ernie:** The goal of today's meeting would seem to be deciding whether or not the group is prepared to proceed with the project.

John King gave brief introductions for the Quantitative Medicine team and gave opening remarks on his hopes for the proceedings and the project. John subsequently turned the floor over to Joshua Kangas.

---

## **II) Interactive Discussion: Quantitative Medicine, Pfizer and Amgen**

Josh provided a tentative agenda for the meeting which included discussion of the ToxCast study design, proposed study designs, and next steps for the group and the project as a whole.

Josh gave a general overview of the active learning concept and the differences between retrospective and prospective studies.

Study guidelines were discussed including the need to define a relevant use case.

Josh described “ToxCast Study I” and defined this study design as Quantitative Medicine’s recommendation for the project.

The Pfizer and Amgen teams expressed their agreement with going forward with the recommended “ToxCast Study I” design for the retrospective study.

---

## **III) Closing Remarks and Action Items**

The Amgen and Pfizer teams requested a list and summary of the assays within ToxCast at Dawn’s suggestion.

Dawn and Amid planned to send out the ToxCast assay information at the conclusion of the meeting.

The Quantitative Medicine team planned to have a results report for the next webinar (date to be determined).

---